As new PrEP products move out of clinical trials and toward market entry, implementation research has a pivotal role to play in guiding the introduction and scale-up of these new products in real-world service delivery settings.

New products, including the dapivirine vaginal ring and injectable cabotegravir, have been approved in several countries, and more biomedical prevention products are in development. As the catalog of HIV prevention products expands, so too does the conversation about the importance of upholding choice to optimize the benefits for potential PrEP users.

We know that adolescent girls and young women live complex lives full of important relationships that shape the decisions they make. Yet too often efforts to generate demand for PrEP fail to reach beyond the individual user to her support system—those trusted people in her life who she leans on when making important choices. But demand generation for PrEP is evolving.

Since oral PrEP was first approved for use in 2012, dozens of countries have approved the product and use is expanding. But the pace of scale-up has been slower than expected and PrEP remains out of reach for many who may benefit from it.

This workshop will explore what is needed to ensure that introductory research and programs are strategically designed, user-centered, and appropriately resourced to support successful rollout of CAB PrEP.